{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:41:46Z","timestamp":1790080906078,"version":"4.0.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,11,8]],"date-time":"2014-11-08T00:00:00Z","timestamp":1415404800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s00280-014-2617-3","type":"journal-article","created":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T05:55:21Z","timestamp":1415944521000},"page":"111-121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies"],"prefix":"10.1007","volume":"75","author":[{"given":"Eleonora","family":"Marostica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juthamas","family":"Sukbuntherng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Loury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier Woot","family":"de Trixhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"De Nicolao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"McGreivy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Italo","family":"Poggesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,8]]},"reference":[{"key":"2617_CR1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Fuman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:32\u201342","journal-title":"N Engl J Med"},{"key":"2617_CR2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369:507\u2013516","journal-title":"N Engl J Med"},{"key":"2617_CR3","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","volume":"120","author":"JA Woyach","year":"2012","unstructured":"Woyach JA, Johnson AJ, Byrd JC (2012) The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 120:1175\u20131184","journal-title":"Blood"},{"key":"2617_CR4","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1200\/JCO.2012.44.4281","volume":"31","author":"A Wiestner","year":"2013","unstructured":"Wiestner A (2013) Targeting B-cell receptor signaling for anticancer therapy: the Bruton\u2019s tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 31:128\u2013130","journal-title":"J Clin Oncol"},{"key":"2617_CR5","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","volume":"117","author":"SEM Herman","year":"2011","unstructured":"Herman SEM, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S et al (2011) Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-3276. Blood 117:6287\u20136296","journal-title":"Blood"},{"key":"2617_CR6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B et al (2013) Bruton tyrosine kinase inhibitor Ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol 31:88\u201394","journal-title":"J Clin Oncol"},{"key":"2617_CR7","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B et al (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 107:13075\u201313080","journal-title":"Proc Natl Acad Sci USA"},{"key":"2617_CR8","doi-asserted-by":"crossref","unstructured":"Poggesi I, Sardu ML, Marostica E, Sukbuntherng J, Chang BY, de Jong J, Woot de Trixhe X, Vermeulen A, De Nicolao G, O\u2019Brien SM, Byrd JC, Advani RH, James DF, Deraedt W, Beaupre D, Wang M (2014). Population pharmacokinetic-pharmacodynamic (PKPD) modeling of ibrutinib in patients with B-Cell malignancies. Accepted for AACR meeting \u201cHematological malignancies: Translating discoveries in novel therapies\u201d September 20\u201323, 2014 Sheraton Philadelphia Downtown Philadelphia, PA, USA","DOI":"10.1158\/1557-3265.HEMMAL14-B19"},{"key":"2617_CR9","volume-title":"User\u2019s guides","author":"S Beal","year":"2009","unstructured":"Beal S, Sheiner LB, Boeckmann A, Bauer RJ, NONMEM (2009) User\u2019s guides. Icon Development Solutions, Ellicott City"},{"key":"2617_CR10","doi-asserted-by":"crossref","DOI":"10.1002\/0470087978","volume-title":"Pharmacometrics: the science of quantitative pharmacology","author":"Ene I Ette","year":"2007","unstructured":"Ette Ene I, Williams Paul J (2007) Pharmacometrics: the science of quantitative pharmacology. Wiley-Interscience, New York"},{"key":"2617_CR11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.0006-341X.2000.00065.x","volume":"56","author":"A Oberg","year":"2000","unstructured":"Oberg A, Davidian M (2000) Estimating data transformations in nonlinear mixed effects models. Biometrics 56:65\u201372","journal-title":"Biometrics"},{"key":"2617_CR12","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4419-9485-1","volume-title":"Pharmacokinetic-pharmacodynamic modeling and simulation","author":"PL Bonate","year":"2011","unstructured":"Bonate PL (2011) Pharmacokinetic-pharmacodynamic modeling and simulation, 2nd edn. Springer, New York","edition":"2"},{"key":"2617_CR13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1023\/A:1018828709196","volume":"16","author":"PL Bonate","year":"1999","unstructured":"Bonate PL (1999) The effect of collinearity on parameter estimates in nonlinear mixed effect modeling. Pharm Res 16:709\u2013717","journal-title":"Pharm Res"},{"issue":"4","key":"2617_CR14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1208\/ps040427","volume":"4","author":"U Wahlby","year":"2002","unstructured":"Wahlby U, Jonsson EN, Karlsson MO (2002) Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci 4(4):27","journal-title":"AAPS PharmSci"},{"key":"2617_CR15","unstructured":"R Development Core Team (2012) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, (URL http:\/\/www.R-project.org )"},{"key":"2617_CR16","unstructured":"DIDB: drug interaction DataBase: University of Washington ( www.druginteractioninfo.org ), Accessed 20 March 2013"},{"key":"2617_CR17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10928-011-9201-9","volume":"38","author":"SX Xu","year":"2011","unstructured":"Xu SX, Dunne A, Kimko H, Nandy P, Vermeulen A (2011) Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models. J Pharmacokinet Pharmacodyn 38:423\u2013432","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2617_CR18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NHG (2008) Mechanism-based concepts of size and maturity. Annu Rev Pharmacol Toxicol 48:303\u2013332","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2617_CR19","unstructured":"Jong de J, Sukbuntherng J, Skee D, Murphy J, O\u2019Brien S, Byrd JC, et al (2014) Evaluation of the pharmacokinetics and food effect of oral ibrutinib in healthy subjects and chronic lymphocytic leukemia patients. AACR annual meeting. Abstract #4637: April 5\u20139"},{"key":"2617_CR20","unstructured":"Imbruvica prescribing information (2013) http:\/\/www.imbruvica.com\/downloads\/Prescribing_Information.pdf . Accessed 24 February 2013"},{"key":"2617_CR21","unstructured":"Sukbuntherng J, Jong de J, Skee D, Pak Y, Fardis M, O\u2019Brien S et al (2014) Pharmacokinetics and safety of ibrutinib with concomitant use of CYP3A inhibitors in patients with B-cell malignancies. ACCP annual meeting"},{"key":"2617_CR22","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1128\/AAC.41.5.898","volume":"41","author":"A Hsu","year":"1997","unstructured":"Hsu A, Granneman GR, Witt G, Locke C, Denissen J, Molla A et al (1997) Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 41:898\u2013905","journal-title":"Antimicrob Agents Chemother"},{"key":"2617_CR23","first-page":"277","volume-title":"Introduction to linear regression analysis","author":"DC Montgomery","year":"1982","unstructured":"Montgomery DC, Peck EA (1982) Introduction to linear regression analysis. Wiley, London, p 277"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2617-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2617-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2617-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T05:54:24Z","timestamp":1566021264000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2617-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,8]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["2617"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2617-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,8]]}}}